Communications BiologyGenomicsPeer-reviewed journal article
Single-cell copy number alteration signature analysis reveals masked patterns and potential biomarkers for cancer
Chenxu WuiD, Ziyu TaoiD, Wen CheniD, Nan WangiD, jinyu WangiD, jiayu Shen, Tao WuiD, Die Qiu, Kaixuan DiaoiD, Xiangyu ZhaoiD, Tianzhu LuiD, Lin ZhangiD, Weiliang Wang, Xinxing LiiD, Xinxiang LiiD, Xiaopeng XiongiD, Xuesong LiuiD
Abstract
Copy number alteration (CNA) is a major type of cancer genome alteration that drives cancer progression. CNA signature analysis can reveal underlying etiology and provide biomarkers for cancer treatment, and existing CNA signature analyzes are all performed using bulk tissue samples. However CNA usually affect large proportion of genome, and the CNA profile of bulk sample does not reflect the actual CNA profiles of the individual cancer cells of the sample, especially in tumors with high heterogeneity, such as hepatocellular carcinoma (HCC). Furthermore, the evolutionary trajectory of CNA mutational processes still remain elusive. Here we build a method to comprehensively analyze the CNA signatures of HCC from single-cell and bulk sample perspective, revealing patterns and potential noise signals from the usually performed bulk tissue CNA signature analysis. Single-cell signature analysis delineated the evolutionary trajectory of HCC CNA signatures, and different CNA signatures consistently emerge in different HCC evolution stages. Single-cell CNA signatures show robust performance in patient prognosis and drug sensitivity prediction. This work not only reveals specific considerations in analyzing CNA signature derived from bulk tissue but also depicts CNA evolution process and provides potential biomarkers for the prognosis and treatment of HCC patients. HighlightSingle-cell analysis reveals CNA signatures masked in bulk tissue. Single-cell analysis delineates the evolutionary trajectory of CNA signature. Small CNAs occur early and large CNAs happens late in HCC evolution. Single-cell CNA signatures show robust performance in guiding cancer clinical treatment.
- organism: human
- assay: whole-genome sequencing
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: statistical model
- approach: experimental assay
- Citations
- 2
- FWCI
- 0.90
- Field percentile
- top 26%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The repertoire of copy number alteration signatures in human cancer
Ziyu Tao, Shixiang Wang, … Xuesong Liu·Briefings in BioinformaticsPeer-reviewed·Jan 28, 2023
- CNSigs: An R Package for the Identification of Copy Number Mutational Signatures
David Tallman, Shawn Striker, … Daniel G. Stover·bioRxiv·Sep 9, 2026
- Signatures of Discriminative Copy Number Aberrations in 31 Cancer Subtypes
Bo Gao, Michael Baudis·Frontiers in GeneticsPeer-reviewed·May 13, 2021
- CNAttention: an attention-based deep multiple-instance method for uncovering CNA signatures across cancers
Ziying Yang, Michael Baudis·bioRxiv·May 26, 2025
- Copy number signature analyses in prostate cancer reveal distinct etiologies and clinical outcomes
Shixiang Wang, Huimin Li, … Xuesong Liu·PLoS GeneticsPeer-reviewed·May 4, 2021
- CNApp: quantification of genomic copy number alterations in cancer and integrative analysis to unravel clinical implications
Sebastià Franch‐Expósito, Laia Bassaganyas, … Jordi Camps·bioRxiv·Jul 16, 2019